IP Library Granted Patent US 8,314,223
Granted Patent B2
US 8,314,223 · App. 12/374,311 · Granted Nov 20, 2012

SDF-1 binding nucleic acids

Assignee: NOXXON Pharma AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,314,223
App. No.
12/374,311
Granted
Nov 20, 2012
Kind
B2
Abstract

The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142, SEQ ID NO:143 or SEQ ID NO:144.

Claims (10)

1. An L nucleic acid, or homolog thereof, wherein said L nucleic acid has the sequence of SEQ ID NO:67 and said homolog has homology to the sequence of SEQ ID NO:67 of at least 85%, and wherein said L nucleic acid and said homolog bind SDF-1.

2. The L nucleic acid of claim 1 , comprising a modification.

3. The L nucleic acid of claim 2 , wherein said modification comprises a polyethylene glycol (PEG) molecule.

4. The L nucleic acid of claim 3 , wherein said PEG is at the 5′ end of said L nucleic acid or said homolog.

5. The L nucleic acid of claim 3 , wherein said PEG is at the 3′ end of said L nucleic acid or said homolog.

6. The L nucleic acid of claim 3 , wherein said PEG is straight chain or branched.

7. The L nucleic acid of claim 3 , wherein said PEG is from about 2 kD to about 200 kD.

8. The L nucleic acid of claim 3 , wherein said PEG is from about 40 kD to about 120 kD.

9. The L nucleic acid of claim 2 , further comprising a linker.

10. The L nucleic acid of claim 2 , wherein said modification comprises a biotin.

Assignments (5)
CHANGE OF NAME Recorded Jan 26, 2023
From: NOXXON PHARMA AG
To: TME PHARMA AG
Reel/Frame 062489/0829 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2020
From: KREOS CAPITAL IV (UK) LIMITED
To: NOXXON PHARMA AG
Reel/Frame 051757/0649 →
SECURITY INTEREST Recorded Apr 27, 2015
From: NOXXON PHARMA AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 035501/0893 →
SECURITY INTEREST Recorded Mar 13, 2014
From: NOXXON PHARMA AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 032422/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2009
From: PURSCHKE, WERNER; JAROSCH, FLORIAN; EULBERG, DIRK; KLUSSMANN, SVEN; BUCHNER, KLAUS; MAASCH, CHRISTIAN; DINSE, NICOLE
To: NOXXON PHARMA AG
Reel/Frame 022216/0668 →
Priority Claims (1)
EP 06014957 · Jul 18, 2006 · regional
Continuity (2)
Continuation PCTEP2007006387 · Jul 18, 2007
Related Publication 20110112172A1 · May 12, 2011